Trial Profile

Multicenter, Triple-arm, Single-stage, Phase II Trial to Determine the Preliminary Efficacy and Safety of RAD001 in Patients With Histological Evidence of Progressive or Metastatic Bone or Soft Tissue Sarcomas.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Alveolar soft part sarcoma; Ewing's sarcoma; Gastrointestinal stromal tumours; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Paraganglioma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
Focus Therapeutic Use
Sponsors Novartis; Novartis Pharmaceuticals

23 Jun 2017 Status changed from active, no longer recruiting to completed.
28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 31 Dec 2016.
28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Dec 2016.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com